WO2019183936A1

WO2019183936A1 - Method for targeted aggregation of magnetic drug and magnet structure

Info

Publication number: WO2019183936A1
Application number: PCT/CN2018/081383
Authority: WO
Inventors: 商澎; 尹大川; 刘雅丽; 陈靖婕; 贾斌
Original assignee: 深圳海磁康科技有限责任公司
Priority date: 2018-03-30
Filing date: 2018-03-30
Publication date: 2019-10-03

Abstract

Disclosed is a method for the targeted aggregation of a magnetic drug, the method comprising the following steps: determining the site of a lesion of a body; making a magnet structure (1), and identifying a focus point (2) that does not coincide with the magnet structure (1); making the lesion coincide with the focus point (2); and applying a magnetic drug to the body according to the characteristics of a magnetic field of the magnet structure (1), so that the magnetic drug aggregates at the site of the lesion. Under the action of the magnetic field generated by the magnet structure (1), the magnetic drug gradually aggregates at the focus point (2) after entering the body, i.e., gradually reaches the site of the lesion, and stays at the site of the lesion to play the role of a drug. Since the focus point (2) does not coincide with the magnetic structure, i.e., being outside of the magnetic structure, the focus point (2) located inside the body can be generated when the magnetic structure is arranged outside the body. Thus, when a lesion is located inside a body, i.e., being a certain distance away from the body surface of the body, a magnetic drug can still aggregate at the site of the lesion by means of the lesion coinciding with the focus point (2), thereby realizing the aggregation of the magnetic drug at a relatively deep site in the body.

Description

Magnetic drug targeted aggregation method and magnet structure

Technical field

The present invention relates to the field of magnetic drug administration, and more particularly to a magnetic drug targeted aggregation method and apparatus.

Background technique

At present, the main technical means for drug targeting, especially for cancer treatment, include active targeting, passive targeting, and physical targeting. Among them, both active and passive targeting achieve drug targeting in vivo through certain rules (such as specific recognition of molecules, deposition of menstrual blood circulation, etc.). These technologies can achieve a certain degree of drug aggregation, but they all have some problems, such as: targeted accuracy, the need for improvement in drug concentration levels. Physical targeting technology uses a physical environment such as temperature or magnetic field to transport the drug to the lesion. This kind of technology can achieve better drug concentration at the appropriate local position, so it has a good development prospect. Among them, the drug targeting technology using a magnetic field often uses a magnetic field to directly transport a magnetic drug combined with superparamagnetic nanoparticles (such as nano-ferric oxide particles) to a lesion site to achieve drug targeting.

At present, the main means of magnetic field drug targeting technology is to use magnets (especially permanent magnets) to attract magnetic nanoparticles, and to attract drugs to specific lesion sites, thereby achieving drug targeting. Since the magnetic nanoparticles are attracted by the magnets, and the magnets tend to use permanent magnets with relatively simple structures, the prior art is more suitable for the lesions in the superficial parts of the body, and there is often no power for the lesions inside the body. In the prior art disclosed, occasional individual techniques are available to achieve drug accumulation in deep lesions in vivo. More typical is the technique of pre-implanting a magnetic needle in the body. This technology can change the magnetic field distribution by implanting magnetic materials, thereby achieving drug accumulation in the deep body. However, this technique is invasive and may cause damage to the body. In addition, there are some deep drug aggregation techniques proposed in the open literature. In fact, it is difficult to truly achieve accurate drug aggregation in deep lesions in the body.

technical problem

The purpose of the present solution is to provide a magnetic drug targeted aggregation method to solve the technical problem that the prior art cannot collect magnetic drugs into the deep part of the body in a non-invasive situation.

Technical solution

In order to achieve the above object, the technical solution adopted by the solution is to provide a magnetic drug targeted aggregation method, comprising the following steps:

S1, determining the location of the lesion of the body;

S2, making a magnet structure, and identifying a focus point that does not coincide with the structure of the magnet;

S3, the lesion is coincident with the focus point;

S4. Apply magnetic drugs to the body according to the magnetic field characteristics of the magnet structure, so that the magnetic drugs gather to the position of the lesion.

Further, in the step S2, the focus point that is not coincident with the structure of the magnet is specifically:

Selecting a straight line in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet;

A maximum point of the magnetic induction intensity on the straight line is determined as a focus point, and the straight line is determined as a focus line.

Further, the step S4 is specifically:

A magnetic drug is applied at any position on the focus line, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.

Selecting a plane in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet;

A maximum point of the magnetic induction in the plane is determined as a focus point, and the plane is determined as a focus plane.

Further, the step S4 is specifically:

A magnetic drug is applied at any position in the focal plane, and the magnetic drug is concentrated by magnetic force to the position of the lesion.

A maximum point of the magnetic induction in a region where the magnetic field generated by the magnet structure and which does not coincide with the structure of the magnet is determined as a focus point.

Further, the step S4 is specifically:

The magnetic drug is applied at any position in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.

The present invention also provides a magnet structure for implementing the magnetic drug targeted aggregation method described above; the magnet structure is a magnetized hollow cylinder, and the magnetization direction of the hollow cylinder is a vertical direction or a horizontal direction; The center of the hollow cylinder is the focus point, and the axis of the hollow cylinder is a line of focus.

The present invention also provides a magnet structure for implementing the magnetic drug targeted aggregation method described above; the magnet structure includes two columns having the same magnetization direction disposed oppositely; a magnetization direction of each of the columns and the column The axes of the bodies are parallel, the cylinders are cylinders or regular hexahedrons, the center of the gap between the two cylinders is the focus point, passing through the focus point and parallel to the axis of the cylinder The plane is the focus plane.

The present invention also provides a magnet structure for implementing the magnetic drug targeted aggregation method described above; the magnet structure includes a ring formed by splicing a plurality of fan rings, and a driving shaft for driving the ring with its own axis as a rotation axis a rotating driving device; magnetization directions between adjacent fan rings are perpendicular to each other, and a center position of the ring is the focus point.

Beneficial effect

After the magnetic drug enters the body, the magnetic field generated by the magnet structure gradually merges to the focus point, that is, gradually reaches the position of the lesion, and stays at the position of the lesion to exert a drug effect. Since the focus point does not coincide with the magnetic structure, that is, it is separated from the magnetic structure, the magnetic structure disposed outside the machine body can generate a focus point inside the body, so when the lesion is located inside the body, that is, when there is a certain distance from the body surface of the body. The magnetic drug can still be collected to the location of the lesion by means of a coincidence of the lesion and the focus point, so as to concentrate the magnetic drug into a deeper part of the body.

DRAWINGS

In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings used in the embodiments or the prior art description will be briefly described below. Obviously, the drawings in the following description are only the solutions of the present embodiment. For some embodiments, other drawings may be obtained from those of ordinary skill in the art in light of the inventive workability.

1 is a flow chart of a magnetic drug targeted aggregation method of the present embodiment;

Figure 2 is a cross-sectional view (when magnetized in the horizontal direction) when the magnet structure is a hollow cylinder;

Figure 3 is a cross-sectional view (when magnetized in the vertical direction) when the magnet structure is a hollow cylinder;

4 is a schematic structural view when the magnet structure is composed of two oppositely disposed cylinders;

5 is a schematic structural view when the magnet structure is composed of two oppositely arranged regular hexahedrons;

6 is a schematic structural view of a first viewing angle when the magnet structure is composed of a plurality of fan rings;

7 is a schematic structural view of a second viewing angle when the magnet structure is composed of a plurality of fan rings;

Figure 8 is a schematic view showing the structure when the magnet structure is a single-winding electromagnet;

Figure 9 is a schematic view showing the structure when the magnet structure is two single-winding electromagnets;

Figure 10 is a schematic view of a three-dimensional focus area when the ring is stationary;

Figure 11 is a schematic view of a three-dimensional focus area realized after the ring is rotated along the axis;

Figure 12 is when the magnet structure is composed of three magnet rods;

In the picture:

1, magnet structure; 2, focus point; 3, hollow cylinder; 4, cylinder; 5, regular hexahedron; 6, ring; 61, fan ring; 7, three-dimensional focus area; 8, magnet rod.

Embodiments of the invention

In order to make the technical problems, technical solutions and beneficial effects to be solved by the present solution more clear, the present embodiment will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present invention and are not intended to be limiting.

It is to be noted that when an element is referred to as being "fixed" or "in" another element, it can be directly on the other element or indirectly. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or indirectly connected to the other element.

It should be understood that the terms "length", "width", "upper", "lower", "front", "back", "left", "right", "vertical", "horizontal", "top" The orientation or positional relationship of the "bottom", "inside", "outside" and the like is based on the orientation or positional relationship shown in the drawings, and is merely for convenience of description of the present scheme and simplified description, and does not indicate or imply the indicated device. Or the components must have a particular orientation, be constructed and operated in a particular orientation, and thus are not to be construed as limiting the present invention.

The implementation of the solution will be described in detail below with reference to specific embodiments.

As shown in FIG. 1 to FIG. 12, the embodiment of the present solution proposes a magnetic drug targeted aggregation method, which includes the following steps:

S1, determining the location of the lesion of the body;

S2, making the magnet structure 1, and identifying the focus point 2 that does not coincide with the magnet structure 1;

S3, the lesion is coincident with the focus point 2;

S4. Applying a magnetic drug to the body according to the characteristics of the magnet structure 1, so that the magnetic drug gathers to the position of the lesion.

In the embodiment of the present solution, the position of the lesion of the body is first determined, the body includes a human body or an animal body; the magnet structure 1 is fabricated as needed, and the focus point 2 of the magnet structure 1 is identified by the detecting device; the lesion and the focus are focused Point 2 is coincident, and then the magnetic drug is applied to the body, specifically, the magnetic drug is injected or the magnetic drug is taken. In this embodiment, the magnetic drug is preferably injected; after the magnetic drug enters the body, the magnetic field generated by the magnet structure 1 is gradually focused. Point 2 confluence, that is, gradually reach the location of the lesion, and stay in the location of the lesion to play a drug role. Since the focus point 2 does not coincide with the magnetic structure, that is, it is separated from the magnetic structure, the magnetic structure disposed outside the machine body can generate the focus point 2 located inside the body, so when the lesion is located inside the body body, that is, the body surface of the body body has a certain degree. At the time of distance, the magnetic drug can still be collected to the position of the lesion by the coincidence of the lesion and the focus point 2, so as to concentrate the magnetic drug to a deeper part of the body.

In the embodiment of the present solution, before the application of the magnetic drug to the body, that is, between step S2 and step S3, the following steps are further included:

S25. Focus verification: verify the magnetic field distribution of the magnet structure 1, confirm the coincidence degree between the magnetic field distribution and the calculation result, and then simulate the process of applying the magnetic drug to confirm the effect of the magnetic drug targeting. To ensure the effect of targeted application. Specifically, the simulated lesion was placed in the magnetic field of the magnet structure 1, and the effect of the final drug aggregation was observed to confirm the effect of the magnetic drug targeting.

Further, referring to FIG. 1 , as a specific implementation manner of the magnetic drug targeted aggregation method provided by the present solution, in step S2, the focus point 2 that is not coincident with the magnet structure 1 is identified as follows:

Selecting a straight line in a region where the magnetic field generated by the magnet structure 1 does not coincide with the magnet structure 1;

The maximum point of the magnetic induction on the straight line is determined as the focus point 2, and the straight line is determined as the focus line.

Specifically, there is a straight line existing in the magnetic field generated by the magnet structure 1, and there is a unique maximum point of the magnetic induction intensity on the straight line, that is, the magnetic induction intensity of other positions on the straight line is smaller than the magnetic induction intensity of the maximum point. , the maximum point is determined as the focus point 2, and the straight line is determined as the focus line, and the area covered by the focus line is the focus area, and the magnetic drug applied in the focus area is affected by the magnetic force due to the difference of the magnetic induction intensity. Converging toward the focus point 2, that is, finally gathering to the lesion, thereby achieving one-dimensional focusing on the focal line.

Further, referring to FIG. 1 , as a specific implementation manner of the magnetic drug targeted aggregation method provided by the present solution, step S4 is specifically:

The magnetic drug is applied at any position on the focal line, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.

Specifically, the magnetic drug can be injected into the body by the blood vessel in the region covered by the straight line, and the magnetic drug merges into the focus point 2 under the action of the magnetic force in the blood vessel, and finally gathers at the lesion. Of course, in the embodiment of the present embodiment, it may also be an oral magnetic drug, which is collected into the lesion by blood circulation through the digestive system.

Selecting a plane in a region where the magnetic field generated by the magnet structure 1 does not coincide with the magnet structure 1;

The maximum point of the magnetic induction in the plane is determined as the focus point 2, and the plane is determined as the focus plane.

Specifically, there is a plane existing in the magnetic field generated by the magnet structure 1, and there is a unique maximum point of the magnetic induction intensity on the plane, that is, the magnetic induction intensity of other positions on the plane is smaller than the magnetic induction intensity of the maximum point. , the maximum point is determined as the focus point 2, and the plane is determined as the focus plane, and the area covered by the focus plane is the focus area, and the magnetic drug in the focus area is affected by the magnetic force due to the difference in magnetic induction intensity. Converging toward the focus point 2, that is, eventually gathering to the lesion, thereby achieving two-dimensional focusing on the focal plane.

The magnetic drug is applied at any position in the focal plane, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.

Specifically, the magnetic drug can be injected into the body through the blood vessel in the region covered by the focus plane, and the magnetic drug merges into the focus point 2 under the action of the magnetic force in the blood vessel, and finally gathers at the lesion. Of course, in the embodiment of the present embodiment, it may also be an oral magnetic drug, which is collected into the lesion by blood circulation through the digestive system.

Further, referring to FIG. 1 , as a specific implementation manner of the magnetic drug targeted aggregation method provided by the present solution, in step S2 , a focus point 2 that does not coincide with the magnet structure 1 is identified:

The maximum point of the magnetic induction in the region where the magnetic field generated by the magnet structure 1 and which does not coincide with the magnet structure 1 is determined as the focus point 2.

Specifically, the magnetic field generated by the magnet structure 1 has a point that does not coincide with the magnet structure 1 and the maximum magnetic induction intensity, and the maximum point is determined as the focus point 2, and the magnetic field generated by the magnet structure 1 does not interact with the magnet structure 1 The position of the coincidence is determined as a focus area, and the magnetic drug in the focus area merges toward the focus point 2 due to the difference in magnetic induction intensity, that is, finally gathers to the lesion, thereby realizing three-dimensional in the magnetic field generated by the magnet structure 1. Focus.

The magnetic drug is applied at any position in the region where the magnetic field generated by the magnet structure 1 does not coincide with the magnet structure 1, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.

Specifically, the magnetic drug can be injected into the body through the blood vessel in the region covered by the magnetic field generated by the magnet structure 1, and the magnetic drug merges into the focus point 2 under the action of the magnetic force in the blood vessel, and finally gathers at the lesion. Of course, in the embodiment of the present embodiment, it may also be an oral magnetic drug, which is collected into the lesion by blood circulation through the digestive system.

As shown in FIG. 2 to FIG. 3, the embodiment of the present invention further provides a magnet structure for implementing the above-mentioned magnetic drug targeted aggregation method; the magnet structure 1 is a magnetized hollow cylinder 3, and the magnetization of the hollow cylinder 3 The direction is vertical or horizontal; the center of the hollow cylinder 3 is the focus point 2, and the axis of the hollow cylinder is a focused line. Specifically, when the above-described magnet structure 1 is used, the lesion is coincident with the focus point 2 so that the magnetic drug in the body gathers to the lesion. For example, the arm is placed in the hollow cylinder 3, the arm is parallel to the axis of the hollow cylinder 3, and the lesion in the arm is coincident with the focus point 2, thereby realizing the accumulation of the magnetic drug in the lesion. At the same time, when the above-mentioned magnet structure 1 is a hollow cylinder 3, it can also be used for a body of the body in the axial direction of the blood vessel, the axial direction of the limbs, and the axial aspect ratio of the animal tail, thereby achieving one-dimensional focusing of the magnetic drug.

In the embodiment of the present solution, the hollow cylinder 3 can be optimally designed to realize product setting and facilitate production.

As shown in FIG. 12, the embodiment of the present embodiment further provides a magnet structure, which is composed of three magnet rods 8. The magnet structure composed of the three magnet rods 8 has a focus point 2 in the magnetic field generated, and there is a focus point. The straight line of 2 has a magnetic induction intensity at any position on the straight line which is smaller than the magnetic induction intensity of the focus point 2, thereby achieving the same effect as the above-described one-dimensional focus.

As shown in FIG. 8 , the embodiment of the present solution further provides a magnet structure, which is a single-winding magnet structure; a focus point 2 is a center position thereof, and a straight line passing through the focus point 2 is a focus line, thereby realizing magnetic properties. One-dimensional focus of the drug. Figure 9 is a structural composition of two of the above single-winding magnets. When the two single-winding magnet structures are stationary, the magnetic induction intensity at any position on the plane of the focus point 2 and the vertical plane of the paper is smaller than the magnetic induction of the focus point 2, Can achieve two-dimensional focus. When the two single-winding magnet structures are rotated along the angle bisector of the angle between themselves, the above-mentioned centering point 2 and the plane of the vertical paper surface are also rotated, that is, the two single-winding magnet structures are rotated. The magnetic induction in the range can achieve a magnetic induction intensity smaller than the focus point 2 at a certain moment, thereby realizing three-dimensional focusing.

As shown in FIG. 4 to FIG. 5, the embodiment of the present invention further provides a magnet structure for implementing the above-mentioned magnetic drug targeted aggregation method; the magnet structure 1 includes two columns of opposite magnetization directions; The magnetization direction of the cylinder is parallel to the axis of the cylinder. The cylinder is a cylinder 4 or a regular hexahedron 5. The center of the gap between the two cylinders is the focus point 2, passing through the focus point 2 and parallel to the axis of the cylinder. The plane is the focus plane. Specifically, when the above-described magnet structure 1 is used, the lesion is coincident with the focus point 2 so that the magnetic drug in the body gathers to the lesion. Since the plane passing through the focus point 2 and parallel to the axis of the cylinder is the focus plane, the magnetic drugs in the plane can gather to the lesion, that is, achieve two-dimensional focusing.

As shown in FIG. 6 to FIG. 7 , the embodiment of the present invention further provides a magnet structure for implementing the above-mentioned magnetic drug targeted aggregation method; the magnet structure 1 includes a ring 6 formed by splicing a plurality of fan rings 61, and The driving device for driving the ring 6 to rotate with its own axis as the rotating shaft; the magnetization directions between the adjacent fan rings 61 are perpendicular to each other, and the center position of the ring 6 is the focus point 2. Specifically, the ring 6 formed by splicing a plurality of fan rings 61, preferably eight fan rings 61 of the same size, form a ring 6, and the magnetization directions of the adjacent fan rings 61 are set to be perpendicular to each other. The central position of the hollow region of the ring 6 is the focus point 2, and the magnetic induction intensity at the position within the partial angle of the hollow region in the ring 6 is smaller than the above-mentioned focus point 2; the drive device is used to drive the ring 6 to rotate with its own axis. The rotation of the shaft enables the 360 degree region of the hollow region in the ring 6 to achieve a magnetic induction intensity smaller than the focus point 2, so that the magnetic drugs in the hollow region in the ring 6 can be concentrated toward the focus point 2, thereby realizing 3D focusing.

In the embodiment of the present embodiment, the magnet structure 1 is any one of a permanent magnet assembly structure, an electromagnet or an electromagnet assembly structure, an electromagnet + permanent magnet hybrid assembly structure, or a time varying electromagnet structure. The above-mentioned magnet structure 1 can also be used for other magnetic field focusing applications in addition to the human body or the animal body, and is not limited herein.

In order to further explain the magnetic induction distribution of the ring structure 6 in which the above-mentioned magnet structure 1 includes a plurality of fan rings 61, please refer to FIG. 10 to FIG. 11. FIG. 10 is a schematic diagram showing the distribution of magnetic induction intensity on the cross section of the ring 6 at rest. The magnetic induction intensity in any position within the three-dimensional focus area 7 is smaller than the magnetic induction intensity of the focus point 2, that is, the accumulation of the medicine is realized in the three-dimensional focus area 7 in FIG. 10, and the partial three-dimensional of the inner ring of the ring 6 is realized. Focus.

Figure 11 is a schematic view showing the distribution of the magnetic induction intensity on the cross section when the ring 6 is rotated 360 degrees along the central axis, that is, the three-dimensional focusing region 7 is covered with the inner ring of the ring 6, and the three-dimensional inner ring of the ring 6 is realized. Focusing, when the lesion coincides with the focus point 2, the magnetic drug at any position of the inner ring of the ring 6 gathers to the lesion. The above manner of realizing three-dimensional focusing by using a rotating magnet structure is defined as a time-averaged local high field, and the time-averaged local high field refers to driving a superparamagnetic particle by using a time-varying magnetic field (time-varying magnetic field) (in this embodiment) Medium magnetic drug) gathers at a fixed location.

It is to be understood that the above-described embodiments of the present invention are merely illustrative of the present invention and are not intended to limit the embodiments of the present invention. Other variations or modifications of the various forms may be made by those skilled in the art in light of the above description. There is no need and no way to exhaust all of the implementations. Any modifications, equivalent substitutions and improvements made within the spirit and principles of this program shall be covered by the scope of the claims.

Claims

A magnetic drug targeted aggregation method, comprising the steps of:

S1, determining the location of the lesion of the body;

S2, making a magnet structure, and identifying a focus point that does not coincide with the structure of the magnet;

S3, the lesion is coincident with the focus point;

S4. Apply magnetic drugs to the body according to the magnetic field characteristics of the magnet structure, so that the magnetic drugs gather to the position of the lesion.
The magnetic drug targeted aggregation method according to claim 1, wherein in the step S2, the focus point that is not coincident with the structure of the magnet is specifically:

Selecting a straight line in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet;

A maximum point of the magnetic induction intensity on the straight line is determined as a focus point, and the straight line is determined as a focus line.
The magnetic drug targeted aggregation method according to claim 2, wherein the step S4 is specifically:

A magnetic drug is applied at any position on the focus line, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.
The magnetic drug targeted aggregation method according to claim 1, wherein in the step S2, the focus point that is not coincident with the structure of the magnet is specifically:

Selecting a plane in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet;

A maximum point of the magnetic induction in the plane is determined as a focus point, and the plane is determined as a focus plane.
The magnetic drug targeted aggregation method according to claim 4, wherein the step S4 is specifically:

A magnetic drug is applied at any position in the focal plane, and the magnetic drug is concentrated by magnetic force to the position of the lesion.
The magnetic drug targeted aggregation method according to claim 1, wherein in the step S2, the focus point that is not coincident with the structure of the magnet is specifically:

A maximum point of the magnetic induction in a region where the magnetic field generated by the magnet structure and which does not coincide with the structure of the magnet is determined as a focus point.
The magnetic drug targeted aggregation method according to claim 6, wherein the step S4 is specifically:

The magnetic drug is applied at any position in a region where the magnetic field generated by the magnet structure does not coincide with the structure of the magnet, and the magnetic drug is concentrated by the magnetic force to the position of the lesion.
A magnet structure, characterized by comprising the magnetic drug targeted aggregation method according to any one of claims 1 to 3; the magnet structure is a magnetized hollow cylinder, and the magnetization direction of the hollow cylinder is vertical Direction or horizontal direction; the center of the hollow cylinder is the focus point, and the axis of the hollow cylinder is a focus line.
a magnet structure, characterized by comprising the magnetic drug targeted aggregation method according to any one of claims 1, 4 or 5; the magnet structure comprises two oppositely disposed cylinders having the same magnetization direction; The magnetization direction of the cylinder is parallel to the axis of the cylinder, the cylinder is a cylinder or a regular hexahedron, and the center position of the gap between the two cylinders is the focus point, passing through the focus point and A plane parallel to the axis of the cylinder is a focal plane.
A magnet structure, characterized by the method for performing the magnetic drug targeted aggregation according to any one of claims 1, 6 or 7; the magnet structure comprises a ring formed by splicing a plurality of fan rings, and a driving base The driving device for rotating the ring with its own axis as a rotating axis; the magnetization directions between adjacent fan rings are perpendicular to each other, and the center position of the ring is the focus point.